Citigroup Inc. (NYSE: C) has emerged from its multi-year restructuring with a historic performance in its investment banking division, reporting record-breaking M&A advisory revenue for the 2025 fiscal year. Despite a volatile start to 2026 that saw the bank’s stock price dip following its fourth-quarter earnings release on
On January 15, 2026, Goldman Sachs (NYSE: GS) silenced critics of its strategic pivot by reporting a powerhouse fourth-quarter performance for 2025, headlined by a staggering $9.34 billion in annual investment banking fees. The firm’s earnings report showcased a definitive return to its roots as the world’s
In a definitive signal that the era of stagnant dealmaking has come to a close, Citigroup (NYSE:C) has reported record-breaking M&A advisory revenue for the fiscal year 2025. The results, unveiled on January 14, 2026, show a bank that has finally turned the corner on a grueling multi-year
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a strategic pivot toward high-growth technology. Morgan Stanley (NYSE: MS) recently released a bullish outlook for the year, projecting a
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone follows a year of aggressive restructuring and a landmark "TrumpRx" partnership that has provided the company with
Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma patients, beating standard treatments with manageable side effects.
In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its lead candidate, tabelecleucel (Ebvallo). The regulatory setback, which the
The United States current account deficit narrowed significantly in the third quarter of 2025, falling to $226.4 billion, or approximately 2.9% of the nation’s gross domestic product (GDP). This marks a substantial improvement from the revised $249.2 billion deficit recorded in the second quarter and signals
As the first quarter of 2026 unfolds, the American corporate landscape is undergoing a massive transformation, driven by the legislative shockwaves of the "One Big Beautiful Bill Act" (OBBBA) of July 2025. What was once feared as a looming "tax cliff" has instead become a high-speed runway for capital expenditure
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a resilient tech economy, healthcare investors were left nursing a "double-digit hangover." In 2024,
As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New J&J" has emerged from the 2023 spin-off of its consumer health division, Kenvue, as a lean, high-margin healthcare powerhouse. Today, the company is [...]
Delaware's top court overturned part of a $1 billion damages award against Johnson & Johnson in the Auris Health merger, ordering a recalculation that could lower payouts.
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion "co-innovation" partnership at the J.P. Morgan Healthcare Conference on January 12, 2026. This five-year strategic alliance aims to re-engineer the
As the final trading bell of January 5, 2026, echoed across the floor of the New York Stock Exchange, a chilling realization set in for market historians and retail investors alike: the legendary "Santa Claus Rally" had failed to materialize for the third consecutive year. This seven-day trading window—spanning
As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic $1 trillion market capitalization threshold in late 2025—the first pure-play pharmaceutical company to do so—Lilly is no longer just a drugmaker; it is a macroeconomic [...]
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (NYSE: ABBV) was in advanced discussions
In a landmark achievement for computational medicine, researchers at Harvard Medical School have developed a "generalist" artificial intelligence model that is fundamentally reshaping the landscape of oncology. Known as the Clinical Histopathology Imaging Evaluation Foundation (CHIEF), this AI system has demonstrated a staggering 98% accuracy in diagnosing rare and metastatic cancers, while simultaneously predicting patient [...]
